Navigation Links
Study Validates Clinical Accuracy of 50% Dose Reduction for Positron Emission Mammography
Date:6/7/2011

SAN ANTONIO, June 7, 2011 /PRNewswire/ -- Presented today at the Society of Nuclear Medicine 2011 Annual Meeting researchers from Swedish Medical Center and the University of Washington showed that FDG dose for Positron Emission Mammography (PEM) may be reduced by at least 50% without altering image quality.

PEM is the breast application of the Naviscan high-resolution PET scanner showing the location as well as the metabolic phase of a lesion.  The metabolic view assists physicians in making the optimal cancer care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term "specificity."  PEM is different than x-ray mammography in that it is currently not used as a screening modality, rather is deployed to confirm extent of disease and aid in treatment planning in a patient already diagnosed with a primary breast cancer.

"With our limited clinical experience with invasive ductal carcinomas to date the clinical diagnostic quality of images appear equivalent between the 5 millicurie (mCi) dose and the traditional 10 millicurie dose. However the longer uptake time (90-120 minutes) we believe significantly improves lesion to background ratio with our invasive ductal carcinomas," stated Dr. James Rogers, a nuclear medicine physician at Seattle Nuclear Medicine and co-author of the study. "The tradeoff between lowering dose and minimally increasing imaging scan time from a 7 to 10 minute scan appears to be a reasonable imaging strategy. We are still formulating our opinion and strategy in regard to lower FDG doses that are less than 5 millicuries, and are hopeful that an individualized patient strategy based on patient weight will allow us to show that lower FDG doses will be possible for a large number of our patients.  We have not done enough DCIS only patients or Invasive Lobular patients to make a conclusion at this time."

The researchers presented results of a study to detect lesions with very low doses of radiation using the Naviscan high-resolution PET scanner.  Preliminary results from five patients with invasive ductal carcinoma as well as phantom images show that PEM lesion detection at a 5 mCi injected dose of FDG, or 50% lower than the dose commonly used in clinical practice, yielded comparable sensitivity while maintaining lesion detectability.  Preliminary results also revealed that injected dose could be reduced further for lighter patients or with concordant increased scan time. These results are part of an ongoing clinical trial at Swedish Medical Center with the goal of determining the lowest optimized dose levels of FDG required to produce high quality PEM images in patients with breast cancer.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.

For more information, including images, videos, quotes and links, please visit the social media news release (SMNR) at http://pitch.pe/151545.


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Finds Patient Adherence to Statin Medications Reduces Hospitalizations and Healthcare Costs
2. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
3. New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
4. Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
5. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
6. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
7. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
8. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
9. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
10. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
11. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... FRANCISCO , March 29, 2017  Spiral ... option agreement with Bionure Farma, S.L. for the ... and to BN119 in the field of otolaryngology ... plus sales-based royalties. The agreement provides Spiral ... assets with a differentiated product profile. Under the ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical cannabis ... the company’s executive management team with prominent executives from both inside and outside the ... Operating Officer, Ted Dumbauld , who has more than twenty years of business ...
(Date:3/29/2017)... ... ... Hamlin Dental Group, multi-location dental office in North Hollywood , Van ... safe and effective options, and can be used alone or in conjunction with other ... care. , Dr. Hamid Reza of Hamlin Dental Group offers other treatments as well, ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 million ... only option for on-premises installation of its Help System for SharePoint was at the ... system into the entire tenant. , The company recently released a modified version ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have ... World Travel Trends Report). As travelers visit both urban destinations, they are faced ... prolonged sun exposure. In response, the outdoor industry has blurred the lines between ...
Breaking Medicine News(10 mins):